200 related articles for article (PubMed ID: 18586313)
21. Longitudinal evaluation of CA-125 velocity and prediction of ovarian cancer.
Xu JL; Commins J; Partridge E; Riley TL; Prorok PC; Johnson CC; Buys SS
Gynecol Oncol; 2012 Apr; 125(1):70-4. PubMed ID: 22198243
[TBL] [Abstract][Full Text] [Related]
22. Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk - Combined Results from Two Screening Trials.
Skates SJ; Greene MH; Buys SS; Mai PL; Brown P; Piedmonte M; Rodriguez G; Schorge JO; Sherman M; Daly MB; Rutherford T; Brewster WR; O'Malley DM; Partridge E; Boggess J; Drescher CW; Isaacs C; Berchuck A; Domchek S; Davidson SA; Edwards R; Elg SA; Wakeley K; Phillips KA; Armstrong D; Horowitz I; Fabian CJ; Walker J; Sluss PM; Welch W; Minasian L; Horick NK; Kasten CH; Nayfield S; Alberts D; Finkelstein DM; Lu KH
Clin Cancer Res; 2017 Jul; 23(14):3628-3637. PubMed ID: 28143870
[No Abstract] [Full Text] [Related]
23. Significance of a single CA 125 assay combined with ultrasound in the early detection of ovarian and endometrial cancer.
Vuento MH; Stenman UH; Pirhonen JP; Mäkinen JI; Laippala PJ; Salmi TA
Gynecol Oncol; 1997 Jan; 64(1):141-6. PubMed ID: 8995563
[TBL] [Abstract][Full Text] [Related]
24. Screening for Ovarian Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
Henderson JT; Webber EM; Sawaya GF
JAMA; 2018 Feb; 319(6):595-606. PubMed ID: 29450530
[TBL] [Abstract][Full Text] [Related]
25. Tumor marker trends in asymptomatic women at risk for ovarian cancer: relevance for ovarian cancer screening.
Cane P; Azen C; Lopez E; Platt LD; Karlan BY
Gynecol Oncol; 1995 May; 57(2):240-5. PubMed ID: 7729742
[TBL] [Abstract][Full Text] [Related]
26. Assessment of symptomatic women for early diagnosis of ovarian cancer: results from the prospective DOvE pilot project.
Gilbert L; Basso O; Sampalis J; Karp I; Martins C; Feng J; Piedimonte S; Quintal L; Ramanakumar AV; Takefman J; Grigorie MS; Artho G; Krishnamurthy S;
Lancet Oncol; 2012 Mar; 13(3):285-91. PubMed ID: 22257524
[TBL] [Abstract][Full Text] [Related]
27. Lung cancer risk prediction: Prostate, Lung, Colorectal And Ovarian Cancer Screening Trial models and validation.
Tammemagi CM; Pinsky PF; Caporaso NE; Kvale PA; Hocking WG; Church TR; Riley TL; Commins J; Oken MM; Berg CD; Prorok PC
J Natl Cancer Inst; 2011 Jul; 103(13):1058-68. PubMed ID: 21606442
[TBL] [Abstract][Full Text] [Related]
28. [Role of Ca 125 in pelvic masses. Our experience].
Rotondi M; Lauro C; Ammaturo FP; Guerriero V; Rasile M; Panariello S
Minerva Ginecol; 2001 Feb; 53(1 Suppl 1):51-4. PubMed ID: 11526720
[TBL] [Abstract][Full Text] [Related]
29. Factors influencing serum CA125II levels in healthy postmenopausal women.
Pauler DK; Menon U; McIntosh M; Symecko HL; Skates SJ; Jacobs IJ
Cancer Epidemiol Biomarkers Prev; 2001 May; 10(5):489-93. PubMed ID: 11352859
[TBL] [Abstract][Full Text] [Related]
30. [The values of serum human epididymis secretory protein 4 and CA(125) assay in the diagnosis of ovarian malignancy].
Dong L; Chang XH; Ye X; Zhu LR; Zhao Y; Tian L; Cheng HY; Li XP; Zhang H; Liao QP; Fu TY; Cheng YX; Cui H
Zhonghua Fu Chan Ke Za Zhi; 2008 Dec; 43(12):931-6. PubMed ID: 19134334
[TBL] [Abstract][Full Text] [Related]
31. The diagnostic performance of CA125 for the detection of ovarian and non-ovarian cancer in primary care: A population-based cohort study.
Funston G; Hamilton W; Abel G; Crosbie EJ; Rous B; Walter FM
PLoS Med; 2020 Oct; 17(10):e1003295. PubMed ID: 33112854
[TBL] [Abstract][Full Text] [Related]
32. The prognostic factor for recurrence in advanced-stage high-grade serous ovarian cancer after complete clinical remission: a nested case-control study.
Wang Q; Zheng Y; Wang P; Zhang J; Liu H; Li Q; Yin R; Bian C; Peng H; Peng Z
J Ovarian Res; 2021 Dec; 14(1):179. PubMed ID: 34930386
[TBL] [Abstract][Full Text] [Related]
33. HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases.
Molina R; Escudero JM; Augé JM; Filella X; Foj L; Torné A; Lejarcegui J; Pahisa J
Tumour Biol; 2011 Dec; 32(6):1087-95. PubMed ID: 21863264
[TBL] [Abstract][Full Text] [Related]
34. Predictive value of CA 125 and CA 72-4 in ovarian borderline tumors.
Lenhard MS; Nehring S; Nagel D; Mayr D; Kirschenhofer A; Hertlein L; Friese K; Stieber P; Burges A
Clin Chem Lab Med; 2009; 47(5):537-42. PubMed ID: 19317653
[TBL] [Abstract][Full Text] [Related]
35. Factors associated with serum CA125 level in women without ovarian cancer in the United States: a population-based study.
Hu X; Zhang J; Cao Y
BMC Cancer; 2022 May; 22(1):544. PubMed ID: 35568827
[TBL] [Abstract][Full Text] [Related]
36. Breast cancer epidemiology according to recognized breast cancer risk factors in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial Cohort.
Lacey JV; Kreimer AR; Buys SS; Marcus PM; Chang SC; Leitzmann MF; Hoover RN; Prorok PC; Berg CD; Hartge P;
BMC Cancer; 2009 Mar; 9():84. PubMed ID: 19292893
[TBL] [Abstract][Full Text] [Related]
37. The UKCTOCS experience--reasons for hope?
Menon U; Kalsi J; Jacobs I
Int J Gynecol Cancer; 2012 May; 22 Suppl 1():S18-20. PubMed ID: 22543913
[TBL] [Abstract][Full Text] [Related]
38. Cumulative incidence of false-positive results in repeated, multimodal cancer screening.
Croswell JM; Kramer BS; Kreimer AR; Prorok PC; Xu JL; Baker SG; Fagerstrom R; Riley TL; Clapp JD; Berg CD; Gohagan JK; Andriole GL; Chia D; Church TR; Crawford ED; Fouad MN; Gelmann EP; Lamerato L; Reding DJ; Schoen RE
Ann Fam Med; 2009; 7(3):212-22. PubMed ID: 19433838
[TBL] [Abstract][Full Text] [Related]
39. [Ca-125 in diagnosis and monitoring of patients with ovarian cancer].
Bocheva Y; Bochev P; Ivanov S
Akush Ginekol (Sofiia); 2015; 54(1):11-7. PubMed ID: 25909124
[TBL] [Abstract][Full Text] [Related]
40. Primary and metastatic ovarian cancer in patients with prior breast carcinoma. Pre-operative markers and treatment results.
Tserkezoglou A; Kontou S; Hadjieleftheriou G; Apostolikas N; Vassilomanolakis M; Sikiotis K; Salamalekis E; Tseke P; Magiakos G
Anticancer Res; 2006; 26(3B):2339-44. PubMed ID: 16821613
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
